Global Recombinant Plasma Protein Therapeutics Market 2019 by Company, Regions, Type and Application, Forecast to 2024

  • receipt Report ID : 190021
  • calendar_today Published On: Sep, 2019
  • file_copy Pages: 119
  • list Pharmaceuticals and Healthcare

The global recombinant plasma protein therapeutics market is driven by various factors such as shift from use of plasma-derived proteins to recombinant therapies, rise in awareness about rare disease management and increased focus on investments in rare diseases. Additionally, steady increase in the number of patients with rare hematological diseases and product approvals by regulatory authorities such as the Food and Drug Administration (FDA), European Commission, and Ministry of Health, Labour and Welfare (Japan) are anticipated to drive the market significantly during the forecast period. However, the high cost of treatment and availability of alternative therapies are likely to restrain the global market.

Scope of the Report:

The global Recombinant Plasma Protein Therapeutics market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024.

The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.

North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Recombinant Plasma Protein Therapeutics.

Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.

This report studies the Recombinant Plasma Protein Therapeutics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Recombinant Plasma Protein Therapeutics market by product type and applications/end industries.

Market Segment by Companies, this report covers

CSL Limited

Shire (Takeda Pharmaceutical Company Limited)

Octapharma

Novo Nordisk

Bayer

Bioverativ Therapeutics, Inc. (Sanofi)

Aptevo Therapeutics

Pharming Group

Pfizer

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Chinese Hamster Ovary (CHO) Cell Line

Baby Hamster Kidney (BHK) Cell Line

Human Embryonic Kidney (HEK) Cell Line

Others

Market Segment by Applications, can be divided into

Hemophilia A

Hemophilia B

Von Willebrand Disease

Others

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

Table of Contents

1 Recombinant Plasma Protein Therapeutics Market Overview

1.1 Product Overview and Scope of Recombinant Plasma Protein Therapeutics

1.2 Classification of Recombinant Plasma Protein Therapeutics by Types

1.2.1 Global Recombinant Plasma Protein Therapeutics Revenue Comparison by Types (2019-2024)

1.2.2 Global Recombinant Plasma Protein Therapeutics Revenue Market Share by Types in 2018

1.2.3 Chinese Hamster Ovary (CHO) Cell Line

1.2.4 Baby Hamster Kidney (BHK) Cell Line

1.2.5 Human Embryonic Kidney (HEK) Cell Line

1.2.6 Others

1.3 Global Recombinant Plasma Protein Therapeutics Market by Application

1.3.1 Global Recombinant Plasma Protein Therapeutics Market Size and Market Share Comparison by Applications (2014-2024)

1.3.2 Hemophilia A

1.3.3 Hemophilia B

1.3.4 Von Willebrand Disease

1.3.5 Others

1.4 Global Recombinant Plasma Protein Therapeutics Market by Regions

1.4.1 Global Recombinant Plasma Protein Therapeutics Market Size (Million USD) Comparison by Regions (2014-2024)

1.4.1 North America (USA, Canada and Mexico) Recombinant Plasma Protein Therapeutics Status and Prospect (2014-2024)

1.4.2 Europe (Germany, France, UK, Russia and Italy) Recombinant Plasma Protein Therapeutics Status and Prospect (2014-2024)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Recombinant Plasma Protein Therapeutics Status and Prospect (2014-2024)

1.4.4 South America (Brazil, Argentina, Colombia) Recombinant Plasma Protein Therapeutics Status and Prospect (2014-2024)

1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Recombinant Plasma Protein Therapeutics Status and Prospect (2014-2024)

1.5 Global Market Size of Recombinant Plasma Protein Therapeutics (2014-2024)

2 Manufacturers Profiles

2.1 CSL Limited

2.1.1 Business Overview

2.1.2 Recombinant Plasma Protein Therapeutics Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 CSL Limited Recombinant Plasma Protein Therapeutics Revenue, Gross Margin and Market Share (2017-2018)

2.2 Shire (Takeda Pharmaceutical Company Limited)

2.2.1 Business Overview

2.2.2 Recombinant Plasma Protein Therapeutics Type and Applications

2.2.2.1 Product A

2.2.2.2 Product B

2.2.3 Shire (Takeda Pharmaceutical Company Limited) Recombinant Plasma Protein Therapeutics Revenue, Gross Margin and Market Share (2017-2018)

2.3 Octapharma

2.3.1 Business Overview

2.3.2 Recombinant Plasma Protein Therapeutics Type and Applications

2.3.2.1 Product A

2.3.2.2 Product B

2.3.3 Octapharma Recombinant Plasma Protein Therapeutics Revenue, Gross Margin and Market Share (2017-2018)

2.4 Novo Nordisk

2.4.1 Business Overview

2.4.2 Recombinant Plasma Protein Therapeutics Type and Applications

2.4.2.1 Product A

2.4.2.2 Product B

2.4.3 Novo Nordisk Recombinant Plasma Protein Therapeutics Revenue, Gross Margin and Market Share (2017-2018)

2.5 Bayer

2.5.1 Business Overview

2.5.2 Recombinant Plasma Protein Therapeutics Type and Applications

2.5.2.1 Product A

2.5.2.2 Product B

2.5.3 Bayer Recombinant Plasma Protein Therapeutics Revenue, Gross Margin and Market Share (2017-2018)

2.6 Bioverativ Therapeutics, Inc. (Sanofi)

2.6.1 Business Overview

2.6.2 Recombinant Plasma Protein Therapeutics Type and Applications

2.6.2.1 Product A

2.6.2.2 Product B

2.6.3 Bioverativ Therapeutics, Inc. (Sanofi) Recombinant Plasma Protein Therapeutics Revenue, Gross Margin and Market Share (2017-2018)

2.7 Aptevo Therapeutics

2.7.1 Business Overview

2.7.2 Recombinant Plasma Protein Therapeutics Type and Applications

2.7.2.1 Product A

2.7.2.2 Product B

2.7.3 Aptevo Therapeutics Recombinant Plasma Protein Therapeutics Revenue, Gross Margin and Market Share (2017-2018)

2.8 Pharming Group

2.8.1 Business Overview

2.8.2 Recombinant Plasma Protein Therapeutics Type and Applications

2.8.2.1 Product A

2.8.2.2 Product B

2.8.3 Pharming Group Recombinant Plasma Protein Therapeutics Revenue, Gross Margin and Market Share (2017-2018)

2.9 Pfizer

2.9.1 Business Overview

2.9.2 Recombinant Plasma Protein Therapeutics Type and Applications

2.9.2.1 Product A

2.9.2.2 Product B

2.9.3 Pfizer Recombinant Plasma Protein Therapeutics Revenue, Gross Margin and Market Share (2017-2018)

3 Global Recombinant Plasma Protein Therapeutics Market Competition, by Players

3.1 Global Recombinant Plasma Protein Therapeutics Revenue and Share by Players (2014-2019)

3.2 Market Concentration Rate

3.2.1 Top 5 Recombinant Plasma Protein Therapeutics Players Market Share

3.2.2 Top 10 Recombinant Plasma Protein Therapeutics Players Market Share

3.3 Market Competition Trend

4 Global Recombinant Plasma Protein Therapeutics Market Size by Regions

4.1 Global Recombinant Plasma Protein Therapeutics Revenue and Market Share by Regions

4.2 North America Recombinant Plasma Protein Therapeutics Revenue and Growth Rate (2014-2019)

4.3 Europe Recombinant Plasma Protein Therapeutics Revenue and Growth Rate (2014-2019)

4.4 Asia-Pacific Recombinant Plasma Protein Therapeutics Revenue and Growth Rate (2014-2019)

4.5 South America Recombinant Plasma Protein Therapeutics Revenue and Growth Rate (2014-2019)

4.6 Middle East and Africa Recombinant Plasma Protein Therapeutics Revenue and Growth Rate (2014-2019)

5 North America Recombinant Plasma Protein Therapeutics Revenue by Countries

5.1 North America Recombinant Plasma Protein Therapeutics Revenue by Countries (2014-2019)

5.2 USA Recombinant Plasma Protein Therapeutics Revenue and Growth Rate (2014-2019)

5.3 Canada Recombinant Plasma Protein Therapeutics Revenue and Growth Rate (2014-2019)

5.4 Mexico Recombinant Plasma Protein Therapeutics Revenue and Growth Rate (2014-2019)

6 Europe Recombinant Plasma Protein Therapeutics Revenue by Countries

6.1 Europe Recombinant Plasma Protein Therapeutics Revenue by Countries (2014-2019)

6.2 Germany Recombinant Plasma Protein Therapeutics Revenue and Growth Rate (2014-2019)

6.3 UK Recombinant Plasma Protein Therapeutics Revenue and Growth Rate (2014-2019)

6.4 France Recombinant Plasma Protein Therapeutics Revenue and Growth Rate (2014-2019)

6.5 Russia Recombinant Plasma Protein Therapeutics Revenue and Growth Rate (2014-2019)

6.6 Italy Recombinant Plasma Protein Therapeutics Revenue and Growth Rate (2014-2019)

7 Asia-Pacific Recombinant Plasma Protein Therapeutics Revenue by Countries

7.1 Asia-Pacific Recombinant Plasma Protein Therapeutics Revenue by Countries (2014-2019)

7.2 China Recombinant Plasma Protein Therapeutics Revenue and Growth Rate (2014-2019)

7.3 Japan Recombinant Plasma Protein Therapeutics Revenue and Growth Rate (2014-2019)

7.4 Korea Recombinant Plasma Protein Therapeutics Revenue and Growth Rate (2014-2019)

7.5 India Recombinant Plasma Protein Therapeutics Revenue and Growth Rate (2014-2019)

7.6 Southeast Asia Recombinant Plasma Protein Therapeutics Revenue and Growth Rate (2014-2019)

8 South America Recombinant Plasma Protein Therapeutics Revenue by Countries

8.1 South America Recombinant Plasma Protein Therapeutics Revenue by Countries (2014-2019)

8.2 Brazil Recombinant Plasma Protein Therapeutics Revenue and Growth Rate (2014-2019)

8.3 Argentina Recombinant Plasma Protein Therapeutics Revenue and Growth Rate (2014-2019)

8.4 Colombia Recombinant Plasma Protein Therapeutics Revenue and Growth Rate (2014-2019)

9 Middle East and Africa Revenue Recombinant Plasma Protein Therapeutics by Countries

9.1 Middle East and Africa Recombinant Plasma Protein Therapeutics Revenue by Countries (2014-2019)

9.2 Saudi Arabia Recombinant Plasma Protein Therapeutics Revenue and Growth Rate (2014-2019)

9.3 UAE Recombinant Plasma Protein Therapeutics Revenue and Growth Rate (2014-2019)

9.4 Egypt Recombinant Plasma Protein Therapeutics Revenue and Growth Rate (2014-2019)

9.5 Nigeria Recombinant Plasma Protein Therapeutics Revenue and Growth Rate (2014-2019)

9.6 South Africa Recombinant Plasma Protein Therapeutics Revenue and Growth Rate (2014-2019)

10 Global Recombinant Plasma Protein Therapeutics Market Segment by Type

10.1 Global Recombinant Plasma Protein Therapeutics Revenue and Market Share by Type (2014-2019)

10.2 Global Recombinant Plasma Protein Therapeutics Market Forecast by Type (2019-2024)

10.3 Chinese Hamster Ovary (CHO) Cell Line Revenue Growth Rate (2014-2024)

10.4 Baby Hamster Kidney (BHK) Cell Line Revenue Growth Rate (2014-2024)

10.5 Human Embryonic Kidney (HEK) Cell Line Revenue Growth Rate (2014-2024)

10.6 Others Revenue Growth Rate (2014-2024)

11 Global Recombinant Plasma Protein Therapeutics Market Segment by Application

11.1 Global Recombinant Plasma Protein Therapeutics Revenue Market Share by Application (2014-2019)

11.2 Recombinant Plasma Protein Therapeutics Market Forecast by Application (2019-2024)

11.3 Hemophilia A Revenue Growth (2014-2019)

11.4 Hemophilia B Revenue Growth (2014-2019)

11.5 Von Willebrand Disease Revenue Growth (2014-2019)

11.6 Others Revenue Growth (2014-2019)

12 Global Recombinant Plasma Protein Therapeutics Market Size Forecast (2019-2024)

12.1 Global Recombinant Plasma Protein Therapeutics Market Size Forecast (2019-2024)

12.2 Global Recombinant Plasma Protein Therapeutics Market Forecast by Regions (2019-2024)

12.3 North America Recombinant Plasma Protein Therapeutics Revenue Market Forecast (2019-2024)

12.4 Europe Recombinant Plasma Protein Therapeutics Revenue Market Forecast (2019-2024)

12.5 Asia-Pacific Recombinant Plasma Protein Therapeutics Revenue Market Forecast (2019-2024)

12.6 South America Recombinant Plasma Protein Therapeutics Revenue Market Forecast (2019-2024)

12.7 Middle East and Africa Recombinant Plasma Protein Therapeutics Revenue Market Forecast (2019-2024)

13 Research Findings and Conclusion

14 Appendix

14.1 Methodology

14.2 Data Source

List of Tables and Figures

Figure Recombinant Plasma Protein Therapeutics Picture

Table Product Specifications of Recombinant Plasma Protein Therapeutics

Table Global Recombinant Plasma Protein Thera

Please fill the form below, to recieve the report sample


+1